Terrific talk by Pedro C Barata, MD MSc FACP at the #WorldGU24 World GU Conference 👉Treatment intensification in mHSPC #prostatecancer 👇Goal is to live longer and better. Convincing argument for doublet therapy for most. UroToday.com OncoAlert Highlights excellent analogy by Irbaz Riaz MD,MS,MBI,PhD Alan H Bryce

What is next after Pluvicto in #prostatecancer treatment, at the #WorldGU24 World GU Conference 👉T 👉 difference between small molecule vs antibody carriers of Lutetium-177, between alpha vs beta radiation and novel RLTs. Comprehensive talk by Praful Ravi UroToday.com OncoAlert

Pros Neeraj Agarwal, MD, FASCO & cons Charles Ryan for combo vs sequential PARPi in CRPC. Very close call for Neeraj Agarwal, MD, FASCO winning the 🥇Honors by Alicia Morgans, MD, MPH

This is a must see talk on anyone interested in focal therapy in RCC #kidneycancer 👉terrific talk by Ulka Vaishampayan 👉multiple applications of focal therapy (radiation/SABR, cryotherapy etc, pros and cons👇KidneyCAN @kidneycancer UroToday.com OncoAlert

Cancer Research Communications Channing Paller Johns Hopkins Medicine Pedro C Barata, MD MSc FACP Congratulations Channing Paller An important (negative) randomized phase 2 trial. Don't add high-dose IV vitamin C when prescribing docetaxel for mCRPC

BRCAaway: Most compelling study suggesting that combined Abi+Olap is better than sequential Abi→Olap or Olap→Abi for BRCA/ATM-altered 1st-line mCRPC. Congrats to Maha Hussain, The PCCTC, Neeraj Agarwal, MD, FASCO, Arul Chinnaiyan, Zachery Reichert, Leonidas Platanias, MD doi.org/10.1158/1078-0…

Proud of Shuchi Gulati MD UC Davis Comprehensive Cancer Cent for leading an effort to characterize outcomes of pts with non-clear cell #kidneycancer in the SWOG Cancer Research Network #EVEREST trial. With such a large denominator, there was a unique opportunity for her to explore this population. Ulka Vaishampayan

Congratulations Pavlos Msaouel & team! This is truly fantastic and so well deserved! MD Anderson Cancer Center

Experts examine findings from the CheckMate 214 trial, which assessed the combination of nivolumab and ipilimumab as a first-line treatment for advanced RCC, focusing on efficacy, safety, and QOL outcomes. Pedro C Barata, MD MSc FACP Martin Voss Wenxin (Vincent) Xu #kcsm onclive.com/view/dr-wulff-…

Toni Choueiri, MD NEJM U.S. FDA ESMO - Eur. Oncology Guillermo de Velasco Mauricio Burotto Cris Roberto Iacovelli Brian Rini, MD Maria Carmen De Santis Fabio Schutz Laurence Albiges Charles Swanton Congrats Toni Choueiri, MD Tom Powles Laurence Albiges Brian Rini, MD and the team for this stupendous work leading to approval of belzutifan for our patients with mccRCC #kidneycancer Kidney Cancer KidneyCAN

POLL Ahead of ESMO - Eur. Oncology 2024 talk on nccRCC: what is your preferred 1st L regimen for advanced, papillary RCC? Vote below! Sumanta K. Pal, MD, FASCO Brian Rini, MD Tom Powles Naomi Haas Uromigos Brian Shuch, MD Neeraj Agarwal, MD, FASCO Yousef Zakharia Rana McKay, MD, FASCO Ulka Vaishampayan Benjamin L Maughan Laura Esfeller

CheckMate-214 at 8 years: Nivolumab + ipilimumab shows durable survival benefit in advanced #RCC. Nizar Tannir, MD, FACP MD Anderson Cancer Center joins Pedro C Barata, MD MSc FACP Case Comp Cancer Ctr to discuss 8yr results in this conversation on UroToday > bit.ly/3UeuE9Q

🔊 For my friends in #NOLA - consider attending kidney cancer patient education meeting with wonderful Marc Matrana Ochsner Health Mary Beth Westerman LSU October 5th Laura Esfeller Scott Delacroix M.D. Kidney Cancer Sumanta K. Pal, MD, FASCO

Excited to share our Journal of Clinical Oncology paper with Dan Petrylak ylt Scott Tagawa Neeraj Agarwal, MD, FASCO Cora Sternberg 𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏 Rohit Jain, MD et al. on SG alone s/p ICI: ORR 32%, mDOR 6 months, rapid responses, should give G-CSF as primary prophylaxis with SG in urothelial Ca! OncoAlert

Happy birthday to Salvatore La Rosa, our Chief Scientific Officer! Your expertise and dedication are truly invaluable to us and we hope you have a fantastic day!

Just in Annals of Oncology 👉on the heels of the recent approval of belzutifan in mRCC #kidneycancer , herein we show in a ph2 randomized trial👉more belzutifan (200 mg vs 120 mg QD) was not better👇Link: tinyurl.com/nrsxp8s4 UroToday.com OncoAlert KidneyCAN Huntsman Cancer Institute

Durvalumab + guadecitabine in metastatic #KidneyCancer. Yousef Zakharia UI Holden Comprehensive Cancer Center discusses phase 1/2 results with Pedro C Barata, MD MSc FACP Case Comp Cancer Ctr and highlights the potential for further research, including the possibility of a triplet combination with IO/TKI > bit.ly/47az1cm

I am delighted to share our manuscript evaluating Tumor Mutational Burden (TMB) and Microsatellite Instability (MSI) in pts with #Urothelialcancer treated with ICIs Thanks to our amazing team Petros Grivas Ali Khaki Rafee Talukder University of Washington Fred Hutchinson Cancer Center sciencedirect.com/science/articl… (1/7)